This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

ADVATE Post Authorization Safety Surveillance

This study has been completed.
Baxter BioScience
Information provided by:
Baxalta US Inc. Identifier:
First received: September 15, 2005
Last updated: June 26, 2015
Last verified: April 2009
The primary objective of this post-authorization safety surveillance is to measure the incidence of adverse events that are at least possibly related to ADVATE use, in subjects receiving ADVATE in routine clinical practice.

Condition Intervention
Hemophilia A Drug: rAHF-PFM

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study

Resource links provided by NLM:

Further study details as provided by Baxalta US Inc.:

Estimated Enrollment: 450
Study Start Date: August 2004
Estimated Study Completion Date: January 2007

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has moderate or severe hemophilia A (baseline FVIII less than or equal to 5%)
  • Subject currently has no measurable FVIII inhibitor titer greater than or equal to 1 BU (Bethesda or Nijmegen method)
  • Subject has been prescribed ADVATE by their treating physician
  • Subject may be of any age
  • Subject or parent/legally authorized representative has provided written informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00214734

  Show 37 Study Locations
Sponsors and Collaborators
Baxalta US Inc.
Baxter BioScience
Study Director: Bruce Ewenstein, MD Baxter BioScience
  More Information Identifier: NCT00214734     History of Changes
Other Study ID Numbers: ADVATE PASS
Study First Received: September 15, 2005
Last Updated: June 26, 2015

Additional relevant MeSH terms:
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn processed this record on September 19, 2017